INNOVACAP

Innova Captab Share Price

₹1,081.05 +24.85 (2.35%)

28 Dec, 2024 01:46

SIP TrendupStart SIP in INNOVACAP

Start SIP

Performance

  • Low
  • ₹1,030
  • High
  • ₹1,108
  • 52 Week Low
  • ₹421
  • 52 Week High
  • ₹1,176
  • Open Price₹1,080
  • Previous Close₹1,056
  • Volume165,772

Investment Returns

  • Over 1 Month + 3.76%
  • Over 3 Month + 41.98%
  • Over 6 Month + 114.56%
  • Over 1 Year + 141.31%
SIP Lightning

Smart Investing Starts Here Start SIP with Innova Captab for Steady Growth!

Invest Now

Innova Captab Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 52.3
  • PEG Ratio
  • 1
  • Market Cap Cr
  • 6,186
  • P/B Ratio
  • 7.4
  • Average True Range
  • 59.24
  • EPS
  • 20.68
  • Dividend Yield
  • 0
  • MACD Signal
  • 27.91
  • RSI
  • 59.66
  • MFI
  • 42.86

Innova Captab Financials

Innova Captab Technicals

EMA & SMA

Current Price
₹1,081.05
+ 24.85 (2.35%)
pointer
  • stock-down_img
  • Bullish Moving Average 16
  • stock-up_img
  • Bearish Moving Average 0
  • 20 Day
  • ₹1,021.80
  • 50 Day
  • ₹950.53
  • 100 Day
  • ₹848.94
  • 200 Day
  • ₹712.68

Resistance and Support

1073.02 Pivot Speed
  • R3 1,193.73
  • R2 1,150.82
  • R1 1,115.93
  • S1 1,038.13
  • S2 995.22
  • S3 960.33

What's your outlook on Innova Captab?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Innova Captab Ltd. is a leading pharmaceutical company in India, specializing in the manufacturing of formulations, including tablets, capsules, and syrups. It caters to domestic and international markets with a focus on quality and innovation.

Innova Captab Ltd has an operating revenue of Rs. 1,177.59 Cr. on a trailing 12-month basis. An annual revenue growth of 17% is outstanding, Pre-tax margin of 12% is healthy, ROE of 11% is good. The company has a reasonable debt to equity of 25%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 14% and 60% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 25% from the pivot point (which is extended from the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 44 which is a POOR score indicating inconsistency in earnings, a RS Rating of 90 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 57 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Innova Captab Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-07 Quarterly Results
2024-08-09 Quarterly Results
2024-05-29 Audited Results
2024-02-13 Quarterly Results
2024-01-18 Quarterly Results

Innova Captab F&O

Innova Captab Shareholding Pattern

50.9%
11.37%
1.89%
1.01%
0%
26%
8.83%

About Innova Captab

  • NSE Symbol
  • INNOVACAP
  • BSE Symbol
  • 544067
  • Managing Director
  • Mr. Vinay Kumar Lohariwala
  • ISIN
  • INE0DUT01020

Similar Stocks to Innova Captab

Innova Captab FAQs

Innova Captab share price is ₹1,081 As on 28 December, 2024 | 01:32

The Market Cap of Innova Captab is ₹6186.3 Cr As on 28 December, 2024 | 01:32

The P/E ratio of Innova Captab is 52.3 As on 28 December, 2024 | 01:32

The PB ratio of Innova Captab is 7.4 As on 28 December, 2024 | 01:32

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23